Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bo Feldt-Rasmussen

Showing results (91-100 of 144) with videos related to

Pageof 15
Sort By:
Diabetes Care|October 20, 2025
Response to Comment on Kofod et al. The Association Between Hemoglobin A1c and Complications Among Individuals With Diabetes and Severe Chronic Kidney Disease. Diabetes Care 2025;48:1400-1409Dea H Kofod, Nicholas Carlson, Thomas P Almdal, et al.
Frontiers in Cell and Developmental Biology|June 30, 2020
Elevated suPAR Is an Independent Risk Marker for Incident Kidney Disease in Acute Medical PatientsEsben Iversen, Morten Baltzer Houlind, Thomas Kallemose, et al.
Cardiovascular Diabetology|June 16, 2023
Cardiovascular mortality in patients with advanced chronic kidney disease with and without diabetes: a nationwide cohort studyDea Haagensen Kofod, Nicholas Carlson, Ellen Freese Ballegaard, et al.
The International Journal of Cardiovascular Imaging|January 21, 2021
Kidney function and the prognostic value of myocardial performance indexNino Emanuel Landler, Rasmus Møgelvang, Susanne Bro, et al.
BMJ Open|April 30, 2013
Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded, parallel intervention studyThomas Idorn, Filip K Knop, Morten Jørgensen, et al.
Blood Purification|September 28, 2021
The Accuracy of Hemoglobin A1c and Fructosamine Evaluated by Long-Term Continuous Glucose Monitoring in Patients with Type 2 Diabetes Undergoing HemodialysisTobias Bomholt, Marianne Rix, Thomas Almdal, et al.
Clinical Kidney Journal|July 9, 2024
Managing cardiovascular risk factors in patients with chronic kidney disease: pharmacological and non-pharmacological interventions in the Copenhagen CKD CohortEllen Linnea Freese Ballegaard, Nicholas Carlson, Morten Buus Jørgensen, et al.
Journal of General Internal Medicine|November 25, 2025
COVID-19 Vaccination and Kidney Disease : SARS-CoV-2 Vaccine Effect on Risk of Infection and Subsequent Outcomes in Patients with Chronic Kidney DiseaseNicholas Carlson, Felix Michalik, Thomas Gerds, et al.
Diabetes Care|August 19, 2015
Safety and Efficacy of Liraglutide in Patients With Type 2 Diabetes and End-Stage Renal Disease: An Investigator-Initiated, Placebo-Controlled, Double-Blind, Parallel-Group, Randomized TrialThomas Idorn, Filip K Knop, Morten B Jørgensen, et al.
Nephron|October 26, 2020
The Glycemic Effect of Liraglutide Evaluated by Continuous Glucose Monitoring in Persons with Type 2 Diabetes Receiving DialysisTobias Bomholt, Thomas Idorn, Filip K Knop, et al.
Pageof 15

Showing results (91-100 of 144) with videos related to

Sort By:
Pageof 15
Diabetes Care|October 20, 2025
Response to Comment on Kofod et al. The Association Between Hemoglobin A1c and Complications Among Individuals With Diabetes and Severe Chronic Kidney Disease. Diabetes Care 2025;48:1400-1409Dea H Kofod, Nicholas Carlson, Thomas P Almdal, et al.
Frontiers in Cell and Developmental Biology|June 30, 2020
Elevated suPAR Is an Independent Risk Marker for Incident Kidney Disease in Acute Medical PatientsEsben Iversen, Morten Baltzer Houlind, Thomas Kallemose, et al.
Cardiovascular Diabetology|June 16, 2023
Cardiovascular mortality in patients with advanced chronic kidney disease with and without diabetes: a nationwide cohort studyDea Haagensen Kofod, Nicholas Carlson, Ellen Freese Ballegaard, et al.
The International Journal of Cardiovascular Imaging|January 21, 2021
Kidney function and the prognostic value of myocardial performance indexNino Emanuel Landler, Rasmus Møgelvang, Susanne Bro, et al.
BMJ Open|April 30, 2013
Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded, parallel intervention studyThomas Idorn, Filip K Knop, Morten Jørgensen, et al.
Blood Purification|September 28, 2021
The Accuracy of Hemoglobin A1c and Fructosamine Evaluated by Long-Term Continuous Glucose Monitoring in Patients with Type 2 Diabetes Undergoing HemodialysisTobias Bomholt, Marianne Rix, Thomas Almdal, et al.
Clinical Kidney Journal|July 9, 2024
Managing cardiovascular risk factors in patients with chronic kidney disease: pharmacological and non-pharmacological interventions in the Copenhagen CKD CohortEllen Linnea Freese Ballegaard, Nicholas Carlson, Morten Buus Jørgensen, et al.
Journal of General Internal Medicine|November 25, 2025
COVID-19 Vaccination and Kidney Disease : SARS-CoV-2 Vaccine Effect on Risk of Infection and Subsequent Outcomes in Patients with Chronic Kidney DiseaseNicholas Carlson, Felix Michalik, Thomas Gerds, et al.
Diabetes Care|August 19, 2015
Safety and Efficacy of Liraglutide in Patients With Type 2 Diabetes and End-Stage Renal Disease: An Investigator-Initiated, Placebo-Controlled, Double-Blind, Parallel-Group, Randomized TrialThomas Idorn, Filip K Knop, Morten B Jørgensen, et al.
Nephron|October 26, 2020
The Glycemic Effect of Liraglutide Evaluated by Continuous Glucose Monitoring in Persons with Type 2 Diabetes Receiving DialysisTobias Bomholt, Thomas Idorn, Filip K Knop, et al.
Pageof 15